

# SCIENTIFIC REPORTS

OPEN

## Early alterations in a mouse model of Rett syndrome: the GABA developmental shift is abolished at birth


N. Lozovaya<sup>1</sup>, R. Nardou<sup>1</sup>, R. Tyzio<sup>1,2</sup>, M. Chiesa<sup>1,2</sup>, A. Pons-Bennaceur<sup>2</sup>, S. Eftekhari<sup>1,2</sup>, T.-T. Bui<sup>1,2</sup>, M. Billon-Grand<sup>1</sup>, J. Rasero<sup>3</sup>, P. Bonifazi<sup>3,4</sup>, D. Guimond<sup>1</sup>, J.-L. Gaiarsa<sup>2</sup>, D. C. Ferrari<sup>1</sup> & Y. Ben-Ari<sup>1</sup>

Genetic mutations of the Methyl-CpG-binding protein-2 (MECP2) gene underlie Rett syndrome (RTT). Developmental processes are often considered to be irrelevant in RTT pathogenesis but neuronal activity at birth has not been recorded. We report that the GABA developmental shift at birth is abolished in CA3 pyramidal neurons of *Mecp2*<sup>-/-</sup> mice and the glutamatergic/GABAergic postsynaptic currents (PSCs) ratio is increased. Two weeks later, GABA exerts strong excitatory actions, the glutamatergic/GABAergic PSCs ratio is enhanced, hyper-synchronized activity is present and metabotropic long-term depression (LTD) is impacted. One day before delivery, maternal administration of the NKCC1 chloride importer antagonist bumetanide restored these parameters but not respiratory or weight deficits, nor the onset of mortality. Results suggest that birth is a critical period in RTT with important alterations that can be attenuated by bumetanide raising the possibility of early treatment of the disorder.

Rett syndrome (RTT) [Online Mendelian Inheritance in Man (OMIM) #312750] is a monogenic, severe disorder due to a genetic mutation of the Methyl-CpG-binding protein-2 (MECP2) gene that affects brain development with an incidence of 1 girl in 10,000–15,000 live births<sup>1</sup>. In addition, even though first considered lethal in the male population, few studies now report this mutation in male patients<sup>2–4</sup>. Symptoms include social withdrawal, frequent seizures, loss of purposeful hand use and expressive language, gait ataxia, mental retardation and respiratory distress<sup>1,5</sup>. Yet, whether a normal early development is followed by a clinical picture is controversial. Indeed, experimental studies using RTT mouse models (*Mecp2*-null or mice with an adult-onset of RTT) suggest that development might not be involved in the history of the disease<sup>6–8</sup>. However, it is now clear that RTT girls have many early pathological signs including abnormal general movements, tongue protrusion, postural stiffness, asymmetric eye opening and closing, hand stereotypies and bursts of abnormal face distortions<sup>9–11</sup>, some that may be present at birth<sup>12–14</sup>. In keeping with this, experimental studies show early gait and sensory and cortical organisation abnormalities in animal models<sup>15</sup>. Yet, in spite of this, we do not know whether these alterations are associated with neuronal electrical abnormalities that may already be present at birth.

Labor and birth are highly complex events in mammals associated with numerous biological changes. There is a release of hormones required to facilitate lungs maturation and the transition from a liquid medium to an aerial one<sup>16–18</sup>. Major alterations of the cardiovascular<sup>19</sup>, immune<sup>20,21</sup> and microbiotic<sup>22</sup> systems also take place. Hence, labor and birth are highly critical periods<sup>23</sup> that when perturbed are associated with many neurodevelopmental disorders<sup>24,25</sup>. In addition, a fundamental issue is whether developmental processes are altered by perinatal insults notably during labor and birth<sup>26–29</sup>. Here, we have investigated whether neuronal activity is already impacted at birth in a mouse model of RTT. We focused on the GABA developmental shift as birth is associated with an abrupt neuroprotective oxytocin-mediated hyperpolarizing GABA action in pyramidal neurons<sup>30</sup>, shift

<sup>1</sup>Neurochlore, Ben-Ari Institute of Neuroarcheology (IBEN), Bâtiment Beret-Delaage, Parc scientifique et technologique de Luminy, 13288, Marseille, cedex 09, France. <sup>2</sup>Mediterranean Institute of Neurobiology (INMED), Department of Neurobiology, Aix-Marseille University, INSERM U1249, 13273, Marseille, France. <sup>3</sup>Biocruces Health Research Institute, 48903, Barakaldo, Spain. <sup>4</sup>IKERBASQUE: The Basque Foundation for Science, 48013, Bilbao, Spain. Correspondence and requests for materials should be addressed to Y.B.-A. (email: [ben-ari@neurochlore.fr](mailto:ben-ari@neurochlore.fr))




**Figure 1.** Depolarizing GABA signaling in hippocampal CA3 pyramidal neurons of  $Mecp2^{-/-}$  newborn and P15 mice. **(a)** Average values of  $DF_{GABA}$  at P0 in wt and  $Mecp2^{-/-}$  neurons. **(b)** Average values of  $DF_{GABA}$  at P0 in control condition and in the presence of bumetanide (10  $\mu$ M) in  $Mecp2^{-/-}$  neurons. **(c)** Representative I/V curves of hippocampal CA3 pyramidal cells at P0 using cell-attached recordings of single  $GABA_A$  channels for the estimation of the  $DF_{GABA}$  in a representative  $Mecp2^{-/-}$  and  $Mecp2^{-/-}$  + bumetanide acute neuron. Inset shows single-channel  $GABA_A$ -mediated currents recorded at imposed voltages ( $-V_p$ , mV) in a  $Mecp2^{-/-}$  P0 pyramidal cell. Dashed lines show the average values of channel openings. Note the two levels of openings at 40 and 60 mV. **(d)** Average values of  $DF_{GABA}$  in wt and  $Mecp2^{-/-}$  neurons at P15. Data are presented as mean  $\pm$  SEM. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ . **(a,b,d)** Significance was determined by two-tailed t-test. (see Supplementary Table 1 for detailed statistics).

that is abolished in the Fragile X (FRX) and intrauterine Valproic Acid (VPA) rodent models of Autism Spectrum Disorders (ASD)<sup>31</sup>. These alterations that persist in juvenile offspring are alleviated by maternal administration of the NKCC1 specific antagonist bumetanide. In addition, bumetanide treatment also attenuates behavioral sequels, suggesting that an alteration of the GABA response at birth is a marker of early abnormalities<sup>31,32</sup>. We now report similar alterations of intracellular chloride concentrations ( $[Cl^-]_i$ ) in a mouse model of RTT that persist in juvenile offspring and are, at least in part, attenuated by bumetanide maternal pretreatment. Results suggest that the  $Mecp2$  mutation impacts neuronal activity at birth with an abolition of the oxytocin-mediated GABA hyperpolarizing shift, stressing its importance in the pathogenesis of RTT.

## Results

**The GABA developmental shift is abolished in RTT.** We first focused on the developmental sequence of  $GABA_A$  receptors ( $GABA_A$ R) currents polarity that is impaired in rodent models of early-life seizures, ASD, FRX and adult RTT<sup>31,33–35</sup>. In naive rodents, the driving force of  $GABA_A$ R-mediated currents ( $DF_{GABA}$ ) is depolarizing in fetal hippocampal CA3 pyramidal neurons shortly before birth, and reduced to slightly depolarizing values at postnatal days 15 to 30 (P15 to P30), with an abrupt oxytocin-mediated hyperpolarization during the delivery period<sup>30,31</sup>. In keeping with this, the  $DF_{GABA}$  for wild-type (wt) mice was slightly hyperpolarizing at P0 in CA3 pyramidal neurons (Fig. 1a). In contrast, in  $Mecp2^{-/-}$  mice, the  $DF_{GABA}$  was elevated at birth, being significantly more depolarizing than for age-matched wt neurons (Fig. 1a and Supplementary Table 1). These differences are due to higher  $[Cl^-]_i$  in neurons in  $Mecp2^{-/-}$  mice since bath application of the NKCC1 chloride importer antagonist bumetanide abolished the depolarizing  $DF_{GABA}$  leading to strongly hyperpolarizing values at P0 (Fig. 1b,c and Supplementary Table 1). Interestingly, this difference was not restricted to birth as the  $DF_{GABA}$  remained elevated two weeks later in  $Mecp2^{-/-}$  mice (P15, Fig. 1d and Supplementary Table 1). In addition, the quantification of overall fluorescence intensity of KCC2 labeling determined by immunohistochemistry revealed




**Figure 2.** Excitatory action of GABA in hippocampal CA3 pyramidal neurons in P15 Mecp2<sup>-/-</sup> mice is rescued by maternal pretreatment with bumetanide. Inhibitory action in wt (a) and excitatory action in Mecp2<sup>-/-</sup> (b,c) of the GABA<sub>A</sub>R agonist isoguvacine (10 μM) on spontaneous spikes recorded in cell-attached configuration. (c) Example of a “bursty” spiking CA3 hippocampal pyramidal cell activity in Mecp2<sup>-/-</sup> mice. (d) Restored inhibitory action of isoguvacine in Mecp2<sup>-/-</sup> mice with bumetanide maternal pretreatment (MP). (a–d) Time-course of spike frequency changes is shown under each trace. (e) Mean values of isoguvacine effects normalized to baseline spike frequency in wt, Mecp2<sup>-/-</sup> mice, and Mecp2<sup>-/-</sup> mice with MP bumetanide. Data are presented as mean ± SEM. \*p < 0.05; \*\*\*p < 0.001. (e) Datasets analyzed by paired sample two-tailed t-test and One-way ANOVA with Fisher’s least significant difference as a post hoc test. (see Supplementary Table 2 for detailed statistics).

a significant reduction of KCC2 expression in the CA3 stratum pyramidale in Mecp2<sup>-/-</sup> slices compared to the wt ones at P15 (Supplementary Fig. 1a,b and Table 1). Therefore, a persistent increase of [Cl<sup>-</sup>]<sub>i</sub> is observed in Mecp2<sup>-/-</sup> neurons starting from birth and maintained at P15.

### GABA excitatory actions in P15 Mecp2<sup>-/-</sup> mice are rescued by maternal pretreatment with bumetanide.

In ASD rodent models, like in a wide range of disorders, high [Cl<sup>-</sup>]<sub>i</sub> is associated with excitatory GABA actions since application of GABA agonists generates action potentials or increases the frequency of action potentials<sup>31,36</sup>. We therefore tested the effects of the GABA<sub>A</sub>R agonist isoguvacine (10 μM) application on CA3 pyramidal neurons at P15 in cell-attached patch clamp recording. In wt neurons, isoguvacine transiently reduced ongoing spike frequency (Fig. 2a,e and Supplementary Table 2). In contrast, isoguvacine significantly increased the frequency of action potentials in age-matched Mecp2<sup>-/-</sup> neurons (Fig. 2b,c,e and Supplementary Table 2). In many Mecp2<sup>-/-</sup> neurons, ongoing activity was characterized by the presence of bursting activity (Fig. 2c). Isoguvacine abolished these bursts that were replaced by high frequency ongoing activity. We then tested the hypothesis that restoring low [Cl<sup>-</sup>]<sub>i</sub> and inhibitory GABA actions specifically during delivery rescues immature electrophysiological features in juvenile offspring. We treated pregnant mice with bumetanide in the drinking water for 1 day at E18 and tested in offspring the effects of isoguvacine at P15. Thus, a single treatment




**Figure 3.** Maternal pretreatment with bumetanide before delivery restores inhibitory GABA actions in *Mecp2*<sup>-/-</sup> mice at P16. **(a)** Representative traces of spontaneous extracellular field potentials recorded in the CA3 zone of hippocampal slices, and effects of isoguvacine (10  $\mu$ M) at P16 in wt, *Mecp2*<sup>-/-</sup> mice, and bumetanide pretreated (MP) *Mecp2*<sup>-/-</sup> mice. Corresponding time courses of spike frequency changes are shown under traces. **(b)** Mean values of isoguvacine effects normalized to baseline spike frequency in wt, *Mecp2*<sup>-/-</sup>, and *Mecp2*<sup>-/-</sup> MP mice. Data are presented as mean  $\pm$  SEM. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ . **(b)** Data set analyzed by repeated measures ANOVA with Tukey's post-hoc test and one-way ANOVA with Tukey's post-hoc test (see Supplementary Table 3 for detailed statistics).

with bumetanide around birth transformed the GABA action recorded in the two-weeks old offspring from excitation to inhibition, as revealed by a reduction of the spike frequency (Fig. 2d,e and Supplementary Table 2). Similar experiments were made with extracellular field potential recordings from the CA3 zone of hippocampal slices (Fig. 3 and Supplementary Table 3). Isoguvacine inhibited spontaneous field potential activity in wt slices but did not affect the frequency of spontaneous field potential activity in *Mecp2*<sup>-/-</sup> slices. These effects differ from the excitation produced by isoguvacine in cell-attached recordings in *Mecp2*<sup>-/-</sup> slices (Fig. 2e); these differences are likely due to the heterogeneity of the population recorded with field recordings including pyramidal neurons but also various types of interneurons. Nevertheless, maternal pretreatment with bumetanide induced GABA inhibitory activity in the *Mecp2*<sup>-/-</sup> P15 hippocampal network.

**Sequential alterations of glutamatergic and GABAergic spontaneous hippocampal network activities in *Mecp2*<sup>-/-</sup> mice.** The balance between excitation and inhibition is instrumental in the operation of brain networks and is disturbed in many disorders including ASD and RTT<sup>31,34,35,37</sup>. This alteration is mediated by either a reduction of inhibition and/or an increased glutamatergic drive. We therefore measured spontaneous GABAergic postsynaptic currents (sIPSC) and glutamatergic postsynaptic currents (sEPSC) at birth and P15 in order to estimate neuronal network excitability as well as the inhibitory/excitatory balance at both developmental stages. To isolate sEPSC from sIPSC, we held the membrane potential at the reversal potentials of inhibitory (-75 mV) and excitatory inputs (+10 mV), respectively. At birth, whole-cell recordings revealed that the frequency and amplitude of sEPSC were significantly increased in *Mecp2*<sup>-/-</sup> mice (Fig. 4a,c,e,i,k and Supplementary Table 4). This was manifested by an increase of charge density (Fig. 4d and Supplementary Table 4). In contrast, neither





**Figure 4.** Spontaneous glutamatergic activity is already increased in Mecp2<sup>-/-</sup> mice at birth. Representative traces of whole-cell voltage clamp recordings of (a) sEPSC at -75 mV and (b) sIPSC at +10 mV from individual hippocampal CA3 pyramidal neurons in hippocampal slices from wt and Mecp2<sup>-/-</sup> mice at P0. (c-h) Average values of sEPSC (c-e) and sIPSC (f-h) frequencies, amplitudes and charge densities (CD,  $\Sigma$ Charge per sec normalized to control) in wt and Mecp2<sup>-/-</sup> mice at P0. (i-l) Cumulative distributions of sEPSC and sIPSC inter-event-interval (iei) and amplitude. Data are presented as mean  $\pm$  SEM. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ . (c-h) Significance was determined by Mann-Whitney test (see Supplementary Tables 4 and 5 for detailed statistics).

the frequency, amplitude nor charge density of sIPSC appeared modified at P0 (Fig. 4b,f-h,j,l and Supplementary Table 5). A different situation prevailed at P15. Even though the amplitude of sEPSC was not found to be altered (Fig. 5g,j and Supplementary Table 6), the frequency was still significantly increased (Fig. 5a,c,j and Supplementary Table 6). Contrarily, the frequency and amplitude of sIPSC were reduced (Fig. 5b,e,h,k,m and Supplementary

Table 7) in *Mecp2*<sup>-/-</sup> mice. Estimation of the charge density of sEPSC and sIPSC revealed an increase of the former and a parallel decrease of the latter (Fig. 5d,f and Supplementary Tables 6, 7) leading to the dramatic net reduction of the sIPSC/sEPSC ratio at P15 (Fig. 5i and Supplementary Table 8). However, frequency and amplitude of miniature GABAergic and glutamatergic PSCs were similar between wt and *Mecp2*<sup>-/-</sup> mice (Supplementary Figs 2a–c; 3a–c and Tables 9 and 10), suggesting that sEPSC and sIPSC alterations are network-mediated. Maternal bumetanide pretreatment restored the sIPSC/sEPSC ratio at P15 in *Mecp2*<sup>-/-</sup> mice including the frequency, amplitude and charge density parameters (Fig. 5c–m and Supplementary Tables 6–8). Therefore, the excitation/inhibition balance is already altered at birth in *Mecp2*<sup>-/-</sup> mice, it persists at P15 and is rescued by maternal bumetanide pretreatment.

**Alterations of spontaneous synapse-driven network oscillations in *Mecp2*<sup>-/-</sup> mice.** Spontaneous activity of CA3 pyramidal neurons in *Mecp2*<sup>-/-</sup> mice is characterized by repetitive population bursts at P15 (Fig. 6a). Thus, 81% of *Mecp2*<sup>-/-</sup> cells display glutamatergic population bursts compared with 30% in wt mice. After maternal pretreatment with bumetanide, only 17% of *Mecp2*<sup>-/-</sup> cells displayed a “bursty” pattern (Fig. 6b and Supplementary Table 11).


To better understand the network alterations in *Mecp2*<sup>-/-</sup> mice, we performed paired recordings from two nearby ( $\leq 200\ \mu\text{m}$ ) CA3 hippocampal pyramidal neurons. Glutamatergic repetitive population bursts were synchronized in pair-recorded *Mecp2*<sup>-/-</sup> cells, as reflected by the Pearson’s correlation coefficient ( $0.39 \pm 0.12$  for *Mecp2*<sup>-/-</sup> vs  $-0.022 \pm 0.036$  for wt mice) (Fig. 6a,c,d and Supplementary Table 11). These synchronized glutamatergic events were blocked by acute bumetanide application, restoring an ongoing activity that is reminiscent of that of wt age-matched neurons, thus suggesting that the excitatory actions of GABA acutely facilitate the generation of synchronized population events (Fig. 6e–g and Supplementary Table 11). Therefore, a high  $[\text{Cl}^-]_i$ -dependent aberrant synchronization is already present in pre-symptomatic *Mecp2*<sup>-/-</sup> mice.

**Metabotropic LTD is altered in *Mecp2*<sup>-/-</sup> mice and corrected by maternal pretreatment with bumetanide.** Common features of mice models of RTT are synaptic plasticity dysfunction, and deficits in learning and memory<sup>38,39</sup>. Indeed, impaired synaptic plasticity was observed in hippocampal slices from *Mecp2*-null mice and in cortical slices from *Mecp2*<sup>308/ly</sup> mice<sup>40,41</sup>, suggesting that these changes in synaptic plasticity consistently result from the loss of *Mecp2*. We therefore examined if the metabotropic glutamate receptors (mGluRs) agonist (S)-3,5-Dihydroxyphenylglycine (DHPG)-induced long-term depression (LTD) at the hippocampal Shaffer collaterals-CA1 synapse in P15 wt and *Mecp2*<sup>-/-</sup> littermates<sup>42</sup>. In brain slices from wt mice, treatment with 50  $\mu\text{M}$  DHPG induced an LTD response that was  $77.83 \pm 1.08\%$  of the baseline fEPSP slope at 50–55 min following washout (we refer it later as late-LTD, Fig. 7a,e and Supplementary Table 12) and  $52.18 \pm 1.56\%$  of the baseline fEPSP slope at 20–25 min following washout (referred to as early-LTD; Fig. 7a,d and Supplementary Table 12). The magnitude of the late-LTD was not significantly different between wt and *Mecp2*<sup>-/-</sup> mice (Fig. 7a,e and Supplementary Table 12). However, early-LTD was significantly decreased in slices from *Mecp2*<sup>-/-</sup> mice compared to wt, suggestive of a deficit in this form of synaptic plasticity (Fig. 7a,d and Supplementary Table 12). Interestingly, in keeping with our hypothesis, maternal pretreatment with bumetanide attenuated the early-LTD deficit in *Mecp2*<sup>-/-</sup> mice (Fig. 7b,c,d and Supplementary Table 12). Therefore, LTD is already impacted in RTT at P15 and corrected by maternal pretreatment with bumetanide.


**Breathing deficiency in *Mecp2*<sup>-/-</sup> mice is not rescued by bumetanide.** *Mecp2*<sup>-/-</sup> young-adult and adult mice have severe cardiorespiratory deficits with irregular breathing patterns and breath-holding, recapitulating human patients symptoms<sup>43,44</sup>. In addition, at P3–P5, breathing patterns and the number of medullary neurons expressing Tyrosine Hydroxylase (TH) are similar in wt and *Mecp2*<sup>-/-</sup> mice, but breathing abnormalities are observed around 6 weeks of age and the number of TH-positive neurons in the medulla is significantly reduced in 2 months old mice<sup>45</sup>. *Mecp2*<sup>-/-</sup> young-adult and adult mice also present low weight compared to controls as early as 4 weeks of age, and a short lifespan<sup>6</sup>. Therefore, we evaluated the breathing patterns of unrestrained mice with whole-body plethysmography along with bodyweight and onset of mortality to test whether bumetanide can rescue these deficiencies in *Mecp2*<sup>-/-</sup> mice. We show that the cumulative probability distribution of the inter-breathing cycle-interval (ICI) of *Mecp2*<sup>-/-</sup> mice differs from wt mice already at P24 (Supplementary Fig. 4a–c and Table 13). Measuring the distance between the ICI datasets in each pair of animals revealed high similarity (i.e. low distance) between animals within the wt group and within the *Mecp2*<sup>-/-</sup> group independently of the maternal pretreatment, but not between the wt and the *Mecp2*<sup>-/-</sup> mice (Supplementary Fig. 4c). Unsupervised clustering analysis of all the mice studied at all ages into the 3 conditions (wt, *Mecp2*<sup>-/-</sup> mice, and *Mecp2*<sup>-/-</sup> + maternal pretreatment with bumetanide) identified with statistical significance ( $p < 0.01$ , see Methods) only two groups corresponding to the wt group and to *Mecp2*<sup>-/-</sup> group with no distinction between treated and untreated animals (Supplementary Fig. 4d and Table 13). We further show that *Mecp2*<sup>-/-</sup> mice were underweight compared to their wt littermates starting at 3.5 weeks and up to 8 weeks of age, and maternal pretreatment with bumetanide did not rescue this deficit (Supplementary Fig. 5a and Table 14). Finally, our results show that maternal pretreatment with bumetanide did not delay the onset of mortality in *Mecp2*<sup>-/-</sup> mice (Supplementary Fig. 5b and Table 15). These results confirm that maternal pretreatment with bumetanide does not ameliorate the breathing patterns, weight gain nor onset of mortality of *Mecp2*<sup>-/-</sup> mice suggesting that hippocampal GABA signaling is not directly contributing to these deficiencies.

## Discussion


Whether RTT is associated with early alterations - clinically or infraclinically - is clearly a complex and controversial issue. Here, we have performed for the first time recordings immediately after birth and showed that cellular and network developmental patterns are already altered at birth and early post-natal life in *Mecp2*<sup>-/-</sup> mice. Indeed, the GABA developmental sequence is affected by this mutation leading to the long-term persistence of



**Figure 5.** Excitation/inhibition ratio is increased in *Mecp2*<sup>-/-</sup> mice at P15 and ameliorated by maternal pretreatment with bumetanide. Representative traces of **(a)** sEPSC and **(b)** sIPSC recorded respectively at  $-75$  mV and  $+10$  mV from individual hippocampal CA3 pyramidal neurons in hippocampal slices from wt, *Mecp2*<sup>-/-</sup> and bumetanide pretreated (MP) *Mecp2*<sup>-/-</sup> mice at P15. Average values of sEPSC **(c,d,g)** and sIPSC **(e,f,h)** frequencies, amplitudes and charge densities (CD,  $\Sigma$ Charge per sec, normalized to control) in wt, *Mecp2*<sup>-/-</sup> mice and *Mecp2*<sup>-/-</sup> MP. **(i)** sIPSC/sEPSC CD ratio in wt, *Mecp2*<sup>-/-</sup> mice with and without MP bumetanide. **(j-m)** Cumulative distributions of inter-event-interval (iei) and amplitude of sEPSC and sIPSC. Data are presented as mean  $\pm$  SEM. \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ . **(c-i)** Data were analyzed with Kruskal-Wallis test with Dunn's multiple comparison post-hoc test (see Supplementary Tables 6-8 for detailed statistics).



**Figure 6.** Hypersynchronization in hippocampal CA3 pyramidal neurons network in Mecp2<sup>-/-</sup> at P15 is rescued by bumetanide. **(a)** Representative traces of dual whole-cell voltage clamp recordings of glutamatergic repetitive population bursts recorded at  $-75$  mV from two neighboring hippocampal CA3 pyramidal neurons in hippocampal slices from P15 Mecp2<sup>-/-</sup> mice. Lower traces are shown at extended timescale. **(b)** Relative contribution of cells displaying population bursts in wt, Mecp2<sup>-/-</sup> and Mecp2<sup>-/-</sup> with MP bumetanide represented in %. **(c)** Representative cross-correlation between sEPSC traces recorded in both cells shown in **(a)**. **(d)** Averaged Pearson's coefficient for dual sEPSC traces. **(e)** Representative traces of sEPSCs from “bursty” hippocampal CA3 pyramidal neurons recorded at  $-75$  mV in Mecp2<sup>-/-</sup> mice with and without acute bumetanide treatment. **(f)** Averaged cumulative probabilities of charge, amplitude and duration of bursts in brain slices of Mecp2<sup>-/-</sup> and Mecp2<sup>-/-</sup> with acute bumetanide treatment. **(g)** Burst mean parameters: charge, amplitude, duration and charge density in Mecp2<sup>-/-</sup> and in Mecp2<sup>-/-</sup> + bumetanide. Data are presented as mean  $\pm$  SEM. \* $p < 0.05$ ; \*\*\* $p < 0.001$ . **(b)** Significance was determined with the two-tailed Fisher's exact test with Bonferroni correction. **(d)** Pearson coefficient in wt and Mecp2<sup>-/-</sup>. **(g)** Datasets were analyzed with the paired sample two-tailed t-test. See Supplementary Table 11 for detailed statistics.



**Figure 7.** Maternal pretreatment with bumetanide rescues impaired mGluR-induced LTD in *Mecp2*<sup>-/-</sup> mice at P15. **(a)** Early phase of DHPG-induced LTD (early -LTD) at the Schaffer Collaterals-CA1 synapses was attenuated in *Mecp2*<sup>-/-</sup> mice 20–25 min following washout of drug, whereas slices from wt mice demonstrated a robust early-LTD. **(b,c)** Maternal pretreatment (MP) with bumetanide restored attenuated early-LTD in *Mecp2*<sup>-/-</sup> mice. **(d)** Averaged fEPSP slope for early-LTD (time window from 20 to 25 min after DHPG washout) and late phase of DHPG-LTD (late-LTD) (time window from 50 to 55 min after DHPG washout) relative to averaged baseline values for wt, *Mecp2*<sup>-/-</sup> and *Mecp2*<sup>-/-</sup> MP with bumetanide mice. Data are presented as mean  $\pm$  SEM. \*\*\**p* < 0.001. Data set analyzed by One-way ANOVA with Fisher's least significant difference post-hoc test (see Supplementary Table 12 for detailed statistics).

GABA excitatory actions. Transient maternal administration of bumetanide around birth induces the recuperation 2 weeks later of inhibitory GABA actions, spontaneous glutamatergic and GABAergic networks activities, and metabotropic LTD similar to age-matched controls. Therefore, already at birth, there are premises of GABA-mediated pathogenic events that might directly or indirectly lead to long-term deleterious sequels. Among these, we evaluated if bumetanide treatment could rescue breathing patterns and weight deficiencies as well as the onset of mortality, and we observed that reducing  $[Cl^-]_i$  levels did not attenuate these sequels. RTT is a complex and multifactorial disorder, so it will be interesting to further evaluate other parameters that were not in the scope of our study. Indeed, in recent studies, we showed that bumetanide attenuates the severity of ASD in two animal models and in children with autism<sup>31,32,46</sup>. As RTT includes cognitive ASD-like symptoms, bumetanide treatment in pilot trials might alleviate some of the manifestations present in RTT patients.

Because of the assumption that RTT is not a developmental disease, studies on the roles played by *Mecp2* during embryonic and early postnatal development have been largely neglected. Yet, clinical studies have now reported consistent impairments before the expression of overt signs<sup>47</sup> with one study particularly describing an hemizygote *MECP2* male patient displaying a severe pathological condition as early as birth<sup>48</sup>. Using high-resolution chromosome microarray analysis to screen 108 fetuses with congenital structural abnormalities, fetuses with the *MECP2* duplication have been identified, presenting ventriculomegaly, hydrocephalus, agenesis of the corpus callosum, choroid plexus cysts, fetal growth restriction and hydronephrosis<sup>49</sup>. In addition, pluripotent stem cells derived from RTT patients or conditionally targeted for *Mecp2* display defective structural and functional maturation<sup>50–52</sup>. In experimental studies, the artificial increase of *Mecp2* levels in chick embryos and mouse neural progenitor cells can impair neurogenesis and lead to premature neuronal differentiation<sup>53,54</sup>. Moreover, a reduction of neuronal responsiveness to stimuli is reported in neuronal cultures of *Mecp2*<sup>-/-</sup> embryonic mice, suggesting, together with previous studies, that *Mecp2* could be a potential modulator of prenatal brain development<sup>55</sup>. In keeping with this, invalidating in part or completely *Mecp2* impacts very early steps of brain maturation, proliferation, migration and neuronal growth<sup>56–58</sup>. Collectively, these observations suggest that *Mecp2* mutations might affect intrauterine development, although this issue deserves direct experimental investigation. However, to the best of our knowledge, only 3 studies have examined early electrical alterations at P14 to P21<sup>45</sup> and P6 to P23<sup>59,60</sup>. Our present results report alterations at birth suggesting that the intrauterine deficiency generated by the mutation might be attenuated or aggravated by labor and birth. Future investigations are required to validate the former or the latter.



The observation that the oxytocin-mediated neuroprotective action of GABA is abolished in RTT with high  $[Cl^-]_i$  present in CA3 pyramidal neurons at birth parallels our earlier studies in the intrauterine VPA and Fragile X rodent models of ASD<sup>31</sup>, and the maternal immune activation (MIA) mouse model that is associated with ASD features<sup>61</sup>. In addition, the developmental GABA shift is also altered in these models leaning to a more depolarized state (also see<sup>34,62</sup>), a pattern of activity similar to the one found in the present study. This result is correlated with the labeling of the neuron-specific chloride exporter KCC2 that is reduced in our *Mecp2*<sup>-/-</sup> mice. Interestingly, other studies have shown similar alterations of KCC2 expression and GABA activity dependent on chloride homeostasis<sup>31,62</sup>. In addition, girls with RTT have reduced KCC2 levels in the cerebrospinal fluid<sup>63</sup> and human neurons derived from pluripotent stem cells from patients with RTT have a significantly reduced KCC2 expression correlated with a delayed GABA switch from an excitatory to an inhibitory action<sup>64</sup>. Moreover, the overexpression of KCC2 rescued the GABA developmental switch deficit in neurons recorded from *Mecp2*-deficient mice<sup>64</sup>, thus inferring that KCC2 is a critical downstream gene target of MeCP2. Altogether, these results reinforce the observation of an interconnection between  $[Cl^-]_i$ , GABA activity, *Mecp2* deficiency and KCC2 expression, defining the pathogenesis of RTT.

What are the mechanistic links between GABA action and this multiplicity of alterations in RTT? Several observations suggest a link between *Mecp2*, chloride co-transporters (such as KCC2) and BDNF. Indeed, there are reciprocal neuronal activity-dependent associations of *Mecp2* with the BDNF promoter<sup>65</sup>, with *Mecp2* transcriptionally regulating BDNF expression<sup>66</sup>. Therefore, it is not surprising to find reduced BDNF levels in *Mecp2*-deficient mice<sup>67</sup>. BDNF is involved in numerous pathways including the proper maturation of the central respiratory rhythm<sup>68</sup>, and the treatment with a BDNF loop-domain mimetic is known to reverse apneas and respiratory abnormalities in *Mecp2*-null mice<sup>69</sup>. BDNF also modulates the development of GABAergic neurons and synapses since GABAergic innervation on the soma of BDNF-lacking neurons is reduced<sup>70</sup>, whereas BDNF overexpression improves neurological symptoms in *Mecp2*-deficient mice<sup>67</sup> (for a review see<sup>71</sup>). In addition, BDNF controls the inhibitory strength of GABA by modulating both the amount of ion flux through open GABA<sub>A</sub> channels and  $[Cl^-]_i$ <sup>72</sup>. Therefore, the GABAergic signals in RTT might be affected because of alterations in BDNF signalization, leading to a loss of the GABA developmental shift with persistent excitatory actions. Future studies should focus on BDNF developmental levels and signalization in combination with bumetanide treatment.

Specific GABAergic signaling alterations have been reported in cortical and brain stem neurons of *Mecp2*-deficient mice. Thus, GABAergic miniature postsynaptic currents in the ventrolateral medulla of P7 mice are altered due to a reduced release of GABA<sup>59</sup>, while increased tonic currents and extrasynaptic GABA<sub>A</sub>R expression are observed in locus coeruleus neurons of 3 weeks old mice<sup>73</sup> (also see<sup>74</sup>). Moreover, in *Mecp2*-mutant mice, the GABA acting agent midazolam alleviates respiratory deficiencies<sup>75</sup>, while phenobarbital rescues dendritic and synaptic defects as well as network activity<sup>76</sup>. Therefore, the critical properties of GABA signaling might be differently impacted in *Mecp2*<sup>-/-</sup> mice depending on the structure observed.

In addition to these distinct GABAergic alterations, a wide range of modifications of the glutamatergic/GABAergic balance have been described in adult rodent models of RTT. Indeed, in the cortex and hippocampus, a reduction of the GABAergic inhibitory tone, altered glutamatergic activity and impaired synaptic inhibition have been reported<sup>77–83</sup>. A consistent observation is an enhanced tendency to hypersynchronous activity<sup>39</sup> that together with the previously described alterations underlies the relatively high incidence of epilepsies in girls with RTT like in animal models<sup>77,84,85</sup>. Interestingly, depending on the type of GABAergic interneurons presenting a loss of *Mecp2*, different RTT features are induced. Thus, selective invalidation of *Mecp2* in parvalbumin-containing interneurons abolishes the critical period plasticity<sup>86</sup> whereas its invalidation in somatostatin interneurons leads to stereotyped behavior and seizures<sup>87</sup>. However, all these studies are performed in adult neurons and therefore not relevant to the issue of developmental alterations in RTT. Yet, determining early pre-clinical changes is important in a cognitive and therapeutic perspective.

Finally, we can hypothesize a direct link in the mechanistic relationship between GABA actions and the early phase of mGluR-dependent LTD. Indeed, three studies have reported that the level of inhibition modulates the amplitude of mGluR-LTD in the hippocampus. Interestingly, in two of them, GABA<sub>A</sub>-receptor-mediated inhibition enhanced mGluR-LTD<sup>88,89</sup>, and in the third one, blocking GABA<sub>A</sub>-receptor-mediated inhibition abolished low frequency stimulation-induced mGluR LTD<sup>90</sup>. Also, other studies have linked chloride homeostasis with glutamatergic synaptic plasticity. Indeed, Deidda *et al.*<sup>91</sup> reported that high frequency stimulation-induced LTP is reduced in Ts65Dn mice (a mouse model of Down syndrome in which GABA remains depolarizing) and bumetanide bath application completely rescued it. In addition, Pavlov *et al.*<sup>92</sup> reported that a GABA<sub>A</sub>-receptor-mediated depolarization is required for the induction of hippocampal NMDA-dependent LTD. We cannot exclude the possibility that persistent depolarizing actions of GABA may have affected the developmental sequence, expression or activity of factors contributing to mGluR-LTD, such as calcium conductance, glutamate receptors expression or kinases/phosphatases actions. Also, because the excitation/inhibition ratio is altered in *Mecp2*-null mice, it is possible that this alteration in ongoing synaptic activity affects the mGluR-LTD.

Maternal administration of bumetanide around birth restored the inhibitory action of GABA 2 weeks later. As the life time of bumetanide is short in infants<sup>93</sup>, a persistence of the agent in offspring can be excluded, thus suggesting that the restoration of low  $[Cl^-]_i$  during a brief period impacts the action of GABA weeks after birth. Maternal bumetanide also attenuated the LTD deficit in slices recorded weeks later, again suggesting long-term effects of interventions during labor and birth. To the best of our knowledge, this is the first evidence that the polarity of GABA at birth can impact synaptic plasticity weeks later. It is difficult at this stage of our knowledge of these long-term effects of bumetanide to speculate on their underlying mechanisms as they could be due to a large number of possibilities including permanent alterations of pre or post-synaptic mechanisms. Indeed,  $[Cl^-]_i$  plays a crucial role on the trophic action that GABA exerts on all developmental mechanisms from proliferation to differentiation, growth, and synapse formation<sup>23,94</sup>. Nevertheless, it is manifest that the critical period of birth impacts the GABA developmental sequence and of synaptic plasticity.



Our results complement similar observations in other pathological conditions. Thus, maternal pretreatment with bumetanide attenuated persistently electrical and behavioral features of ASD in the intrauterine VPA and the Fragile X rodent models<sup>31,32</sup>, reinforcing the suggestion that short-term treatment with bumetanide induces long-term beneficial effects. Early oxytocin (OT) administration also attenuated the long-term sequels of neonatal maternal separation, notably pain sensitivity that is restored in adults<sup>95</sup>. OT and bumetanide exert analgesic actions on pups by reducing  $[Cl^-]$ , and restoring GABAergic inhibition in pain pathways<sup>96</sup>. Similarly, postnatal administration of OT during early life in both babies and mice deficient for *Magel2* prevents feeding deficiency in pups as well as social and memory deficits in adults<sup>97–100</sup>. It is suggested that GABAergic and glutamatergic activities during labor and birth exert long-term sequels by impacting essential early sensory interactions between the mother and pups, reinforcing the idea that labor and birth are critical periods<sup>23</sup>. Interestingly, birth itself acts as an active trigger to accelerate circuit formation of the barrel cortex and suction<sup>101,102</sup>. Given that the loss of *Mecp2* results to a dysregulation of a large number of pathways already at birth, early interventions might prevent the vicious cycle triggered by early insults. Bumetanide however failed to correct several general clinical parameters including breathing deficiency and weight gain as well as the onset of mortality in *Mecp2*<sup>-/-</sup> offspring, suggesting that the polarity of GABA at birth is not involved in these mechanisms. This also raises the possibility that some of the pathogenic events have a different developmental sequence occurring after birth consistently with the observation that respiration and weight gain are normal at first then present a delayed regression<sup>45</sup>. Determining whether bumetanide attenuates some of the functionalities impacted in RTT will require additional experiments testing a plethora of clinical and behavioral signs.

In conclusion, results suggest that birth is a critical period in the pathogenesis of *Mecp2*<sup>-/-</sup> mice. Developmental sequences are of clear importance in the pathogenesis of RTT and must be investigated as early as birth. Studies on the bidirectional links between intrauterine development, labor and birth are of paramount importance. Unfortunately, our understanding of these events is limited by the paucity of experiments centered on this critical period. A convergence of experimental observations stresses the importance of the delivery-associated GABA developmental shift and the long-term consequences of its abolition by genetic or environmental intrauterine insults. These experimental observations are reinforced by the clinical efficacy of bumetanide to treat ASD. Although we do not know how administration of a drug restricted to the critical period of birth leads to such long-term effects, understanding the developmental alterations associated with this period is instrumental in a therapeutic perspective.

## Material and Methods

**Mice.** Experiments were performed on *Mecp2*-null (*Mecp2*<sup>-/-</sup>) and wt (*Mecp2*<sup>+/-</sup>) littermate mice maintained on a C57BL/6 background<sup>6</sup>. All experiments were conducted in accordance with the European Community Council Directives (2010/63/UE) and approved by the local ethics committee (CEEA n°14) and French Ministry for Research (Project #16370-2018073116436588). Postnatal mice and litters were randomly assigned for recordings except for the cohort of the LTD experiments.

**Slice preparation.** *Mecp2*<sup>-/-</sup> and wt littermates (P0, P14–P16) were euthanized by decapitation. The brain was rapidly removed and placed in an oxygenated ice-cold choline solution containing (in mM): 132.5 choline chloride, 2.5 KCl, 0.7 CaCl<sub>2</sub>, 3 MgCl<sub>2</sub>, 1.2 NaH<sub>2</sub>PO<sub>4</sub>, 25 NaHCO<sub>3</sub> and 8 glucose; oxygenated with 95% O<sub>2</sub> and 5% of CO<sub>2</sub>. Transverse 300–400 μm-thick horizontal slices were cut using a vibratome (Leica VT1000S; Leica Microsystems, Germany) in ice-cold choline solution oxygenated with 95% O<sub>2</sub> and 5% of CO<sub>2</sub>. Before recording, slices were incubated in an artificial cerebrospinal fluid (ACSF) solution (see compositions below) equilibrated at pH 7.4 with 95% O<sub>2</sub> and 5% CO<sub>2</sub> at room temperature (22–25 °C) for at least 1 h to allow recovery. For the recordings, slices were placed into the recording chamber where they were fully submerged and superfused with oxygenated ACSF solution at room temperature (22–25 °C) and at 34 °C for LTD experiments. For the recordings of glutamatergic and GABAergic spontaneous activities, we used ACSF with the following composition (in mM): 125 NaCl, 3.5 KCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 26 NaHCO<sub>3</sub> and 10 glucose. For single-channel, extracellular field potential, miniature postsynaptic currents (mPSCs) and LTD, recordings we used ACSF containing (in mM): 126 NaCl, 3.5 KCl, 2 CaCl<sub>2</sub>, 1.3 MgCl<sub>2</sub>, 1.2 NaH<sub>2</sub>PO<sub>4</sub>, 25 NaHCO<sub>3</sub> and 11 glucose.

**Electrophysiological recordings.** *Cell-attached recordings.* Cell-attached recordings of action potentials firing were performed in CA3 pyramidal cells at  $V_p = 0$  mV with an EPC-10 amplifier (HEKA Elektronik Dr Schulze GmbH, Germany) using 8–10 MΩ borosilicate glass pipettes filled with ACSF. Isoguvacine (10 μM) was applied locally with a microfluidic pipette for the time necessary to reach saturation of isoguvacine effects. Recordings of single GABA<sub>A</sub> receptor channels in cell-attached configuration were performed in CA3 pyramidal cells using an EPC-10 amplifier (HEKA Elektronik Dr Schulze GmbH, Germany). Patch pipette solution for recordings of single GABA<sub>A</sub> channels contained (in mM): 120 NaCl, 5 KCl, 20 TEA-Cl, 5 4-aminopyridine, 0.1 CaCl<sub>2</sub>, 10 MgCl<sub>2</sub>, 10 glucose, 10 HEPES-NaOH buffered to pH 7.3 and GABA (5 μM). Pipettes had a resistance in the range of 7–10 MΩ. We performed conventional cell-attached recordings of currents through GABA<sub>A</sub> channels after gigaseal formation (>3 GΩ). Currents through GABA<sub>A</sub> channels were recorded from –100 to +60 mV with 10 mV increments for 1–2 minutes for each holding potential, depending on the ongoing frequency of GABA<sub>A</sub> channels openings, to obtain at least 20 single-channel openings for each potential. Bumetanide (acute, 10 μM) was added in the bath solution for 15 minutes before single-channel recordings. Action potential frequency and single-channels recordings were analyzed using Clampfit 10.4 (Molecular Devices, CA, USA) and OriginPro (OriginLab Corporation, MA, USA) softwares. The exclusion criteria for recordings were insufficient signal-to-noise ratio, insufficient number of channel openings, presence of strong irregular artefact signals, strong baseline oscillations, short dwell time of channels, too fast desensitization of channels or presence of non-specific conductances. We also excluded sublevel channel openings using threshold detection.

**Whole-cell recordings.** Whole-cell recordings of CA3 pyramidal neurons were performed using an EPC-10 amplifier (HEKA Elektronik Dr Schulze GmbH, Germany). Patch pipette solution contained (in mM): 130 K-gluconate, 10 Na-gluconate, 7 NaCl, 4 Mg-ATP, 10 HEPES, 4 phosphocreatine, 0.3 Na-GTP, pH 7.3 with KOH. Spontaneous GABAergic postsynaptic currents (sIPSC) were recorded for 15 min at the reversal potential for glutamatergic currents (+10 mV), and spontaneous glutamatergic postsynaptic currents (sEPSC) were recorded for 10 min at the reversal potential for GABAergic currents (−75 mV). We defined as a burst a minimum of three sEPSC associated with a baseline elevation of the amplitude of minimum 60 pA. Bumetanide (acute, 10 μM) was added in the bath solution for 20 minutes before sEPSC or sIPSC recordings.

Miniature postsynaptic currents (mPSCs) were recorded in whole-cell voltage-clamp configuration with a MultiClamp 700B amplifier (Molecular Devices, CA, USA). To record miniature excitatory postsynaptic currents (mEPSC), micropipettes (6–8 MΩ) were filled with the following recording solution (in mM): 130 K-gluconate, 10 Na-Gluconate, 4 NaCl, 10 HEPES, 4 phosphocreatine, 4 Mg-ATP and 0.3 Na-GTP and recordings were performed at −70 mV in the presence of TTX (1 μM) and gabazine (5 μM). To record miniature inhibitory postsynaptic currents (mIPSC), micropipettes (4–6 MΩ) were filled with the following recording solution (in mM): 130 KCl, 10 HEPES, 1.1 ethylene glycol-bis (β-aminoethyl ether)-N,N,N',N'-tetra-acetic acid (EGTA), 0.1 CaCl<sub>2</sub>, 5 phosphocreatine, 4 Mg-ATP and 0.4 Na-GTP and recordings were performed at −70 mV in the presence of TTX (1 μM) and CNQX (10 μM). All following parameters were controlled to be within acceptable and similar range across recordings: series resistance, membrane capacitance, resting membrane potential (i.e. membrane potential when  $I = 0$ ,  $V_{rest}$ ), firing pattern and holding current.

Cells with holding currents >−30 pA (for P0) and >−40 to −50 pA (for P15) at holding potential −70 mV were excluded from analysis. Holding current and input resistance were constantly monitored and cells with >15% shift of these parameters during the recordings were excluded from analysis.

Spontaneous and miniature IPSC and EPSC were analyzed using Mini Analysis 6.0.7 (Synaptosoft, GA, USA) and OriginPro (OriginLab Corporation, MA, USA) softwares.

For MiniAnalysis the threshold for events detection was defined as 3 times the standard deviation of the noise. The exclusion criteria for recordings were insufficient signal-to-noise ratio, baseline oscillations and distorted shape of synaptic events. mIPSC and mEPSC were analyzed by an investigator blind to the genotype.

**Extracellular recordings.** Extracellular field potential recordings were performed in the CA3 pyramidal layer of *Mecp2*<sup>−/y</sup> and wt littermates using glass pipettes (Harvard Apparatus, MA, USA) containing ACSF. Extracellular field potentials were recorded with a DAM-80A amplifier (WPI, UK) with a low-pass filter at 1 Hz and high-pass filter at 3 kHz. Data were digitized online with a Digidata 1400A digitizer (Molecular Devices, CA, USA) and analyzed using Clampfit 10.4 software (Molecular Devices, CA, USA). Isoguvacine (10 μM) was directly added to the perfusion solution for 90 s. The threshold for spike detection was defined as 3 times the standard deviation of the noise recorded in the bath solution. We calculated the spike frequency for control, isoguvacine and wash-out periods, and if the latter did not come back to control levels (±20% of control), the slice was excluded from the analysis.

For LTD experiments, a bipolar stimulating electrode made from twisted nichrome wire (66 μm; A-M Systems, WA, USA) was placed on the surface of the stratum radiatum of CA1 to stimulate the Schaffer collaterals/commissural fibers (10–50 μs, 5–15 V, 0.03 Hz). Extracellular 50 μm tungsten electrodes (California Fine Wire, CA, USA) were used to record dendritic field excitatory postsynaptic potentials (fEPSP) from the stratum radiatum of the CA1 region. The signals were amplified using a DAM80 amplifier (WPI, UK), digitized with an Axon Digidata 1550B (Molecular Devices, CA, USA), recorded with Axoscope software version 8.1 (Molecular Devices, CA, USA) and analyzed offline with Mini Analysis Program version 6.0 (Synaptosoft, GA, USA) by measuring the onset (a 30–70% rising phase) slope of the fEPSP. LTD was induced with (S)-3,5-Dihydroxyphenylglycine (DHPG, 50 μM for 5 min). The inclusion criteria of slices consisted on a stable and high quality basal synaptic response for at least 20 minutes after stimulation and before applying the DHPG protocol.

**Immunohistochemistry.** At P15, wt and *Mecp2*<sup>−/y</sup> mice were perfused intracardially with antigenfix (Diapath, Italy) and brains were sliced (70 μm thickness) using a Leica VT1000S vibratome (Leica Microsystems, Germany). Selected sections from wt and *Mecp2*<sup>−/y</sup> hippocampi were processed in parallel for immunohistochemistry under identical conditions. Sections were incubated for 1 h at room temperature, with a mixture of 5% normal goat serum (NGS, Jackson ImmunoResearch Laboratories, Inc., PA, USA) in 0.1 M phosphate buffered saline (PBS, Life Technologies, CA, USA) with 0.3% Triton X-100 (Sigma-Aldrich, MO, USA). They were then incubated overnight at 4 °C with the anti-KCC2 antibody (rabbit; 1/800; US Biological, MA, USA) diluted in PBS with NGS 1% and 0.1% Triton X-100. After being washed in PBS, sections were incubated for 1 h at room temperature with the fluorescent-labeled secondary antibody Alexa Fluor 555 (1/1000, Life Technologies, CA, USA) diluted in PBS. Sections were finally mounted on slides and imaged on a SP5X Leica confocal microscope (Leica Microsystems, Germany) using identical settings (2 hippocampal hemispheres of 3 sections per animal). KCC2 immunofluorescence analysis of the whole CA3 pyramidal layer within the image was performed blindly using the open-source platform Fiji (1.50e, Java 1.8.0\_60, 64-bit; <https://fiji.sc/>)<sup>103</sup>.

**Plethysmography experiments.** 3 groups of mice were used at different ages in this study: wt, *Mecp2*<sup>−/y</sup> and *Mecp2*<sup>−/y</sup> pretreated with bumetanide (see the Supplementary Table 13).

**Plethysmographic recording.** Breathing of unrestrained, non-anesthetized mice was recorded using constant air flow whole-body plethysmography filled with air (EMKA Technologies, France) at different ages for each mouse (from 3.5 to 8 weeks old). Four plethysmography chambers of 200 mL containing air (calibrated by injecting 1 mL

of air) maintained at  $25 \pm 0.5^\circ\text{C}$  were used to allow simultaneous measurements. Breathing cycles were recorded for 1 h under normal-ventilation conditions after an adaptation phase of 1 h in the experimental room and 44 min in the recording chamber. All animals evaluated for respiration were included in the analysis.

**Analysis.** Analog signals were obtained using an usbAMP device equipped with four inputs and processed using EMKA technologies IOX software (EMKA Technologies, France). Data analyses were carried out using MatLab software (MathWorks, MA, USA).

One breathing cycle consisted of a period of inspiration followed by a period of expiration. Plethysmography signals were converted into EDF files and analyzed using custom-developed analysis software in MatLab (MathWorks, MA, USA). For each animal, analysis was conducted on the time window of 1 h following the animal adaptation. In order to identify the positive and negative parts of a breathing cycle, the signal  $s(t)$  was first pre-processed through double thresholding and transformed into a trinary time series  $b(t)$  according to the following (where  $t$  is the time frame):

$$\begin{aligned} b(t) &= 1 \text{ for } s(t) > 0.15 \\ b(t) &= -1 \text{ for } s(t) < -0.4 \\ b(t) &= 0 \text{ for } -0.4 \leq s(t) \leq 0.15. \end{aligned}$$

Next, a moving average over 25 frames was applied to  $b(t)$  to smooth over local fluctuations and again converted into a trinary time series by setting positive (negative) values to one (minus one). This entire pre-processing procedure allowed to reliably identify the positive and negative parts of signals corresponding to the two phases of the breathing cycles (inspiration and expiration respectively). The beginning of positive epochs, characterized by consecutive positive values in the time series, was used as the starting timing of the positive cycles. Similar analysis was done to identify the starting timing of the negative cycles. The analysis described in this paper refers to the interval between consecutive positive cycles with at least a negative cycle in between (inter-breathing cycle-interval, ICI). However, no statistical difference was observed when we considered the opposite case, i.e. the interval between negative cycles.

For each animal, the cumulative probability of the ICI was calculated (shown in Supplementary Fig. 4b). The matrix displaying the distance between the ICI datasets from each pair of animals was calculated using the Cliff's Delta effect size coefficient (Supplementary Fig. 4c)<sup>104</sup>. Hierarchical clustering analysis was performed on the Cliff's Delta matrix using a cosine distance (as depicted in Supplementary Fig. 4d) and was aimed at identifying three groups in the dataset. The statistical significance of the clustering result was assessed in relation to the probability distribution obtained in random classifications which is given by a binomial distribution with three possible choices and a number of repetitions equal to the number of animals per group. Concerning the statistical power, the  $p$ -values calculated from the binomial distribution for the number of animals classified in each group (as shown in Supplementary Fig. 4d) were lower than  $10^{-18}$ .

**Weight gain and life span.** *Wt*, *Mecp2*<sup>-/-y</sup> and *Mecp2*<sup>-/-y</sup> mice pretreated with bumetanide were weighted weekly from 3.5 to 8 weeks of age, and the day of death was noted as the onset of mortality. *Wt* mice were evaluated for the onset of mortality until 30–38 weeks of age. All animals randomly assigned for these tests were analyzed by an investigator blind to the treatment and genotype.

**Pharmacological agents and bumetanide pretreatment.** *In vitro*. Bumetanide (10  $\mu\text{M}$ , Sigma-Aldrich, MO, USA), isoguvacine (10  $\mu\text{M}$ , Sigma-Aldrich, MO, USA), TTX (1  $\mu\text{M}$ , Abcam, Bristol, UK), CNQX (10  $\mu\text{M}$ , Sigma-Aldrich, MO, USA), gabazine (5  $\mu\text{M}$ , Tocris Cookson, Bristol, UK) and DHPG (50  $\mu\text{M}$ , Tocris Bioscience, UK) were directly added to the perfusion solutions.

*In vivo*. Pregnant mice were randomly assigned for bumetanide pretreatment (2.5 mg/kg) administered in the drinking water.

**Statistical analysis.** Datasets were first tested for normality. If the datasets fit a normal distribution, a parametric method was used, and if not, a nonparametric method was used. Electrophysiological studies were analyzed with the two-tailed  $t$ -test, paired sample two-tailed  $t$ -test, Mann-Whitney test, two-tailed Fisher's exact test with Bonferroni correction, one-way analysis of variance (ANOVA) with Fisher's least significant difference (LSD) or Tukey's post-hoc tests, repeated measures ANOVA with Tukey's post-hoc test, and Kruskal–Wallis with Dunn's multiple comparison post-hoc test (see Supplementary material for descriptive statistics). KCC2 immunofluorescence was analyzed with the Mann-Whitney test. Plethysmography studies were analyzed as described in the previous section. Weight gain and life span were analyzed with one-way ANOVA with Bonferroni post-hoc test. Analyses were performed with GraphPad Prism 7 (GraphPad Software, CA, USA) or OriginPro (OriginLab Corporation, MA, USA). Statistical power was analyzed using AnaStats tools (Anastats Scop ARL, France). All data are presented as mean  $\pm$  SEM. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ .

## Data Availability

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

## References

1. Amir, R. E. *et al.* Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat. Genet.* **23**, 185–188 (1999).
2. Villard, L. MECP2 mutations in males. *J. Med. Genet.* **44**, 417–423 (2007).
3. Orrico, A. *et al.* MECP2 mutation in male patients with non-specific X-linked mental retardation. *FEBS Lett.* **481**, 285–288 (2000).

4. Meloni, I. *et al.* A mutation in the rett syndrome gene, MECP2, causes X-linked mental retardation and progressive spasticity in males. *Am. J. Hum. Genet.* **67**, 982–985 (2000).
5. Percy, A. K. *et al.* Rett syndrome diagnostic criteria: lessons from the Natural History Study. *Ann. Neurol.* **68**, 951–955 (2010).
6. Guy, J., Hendrich, B., Holmes, M., Martin, J. E. & Bird, A. A mouse *Mecp2*-null mutation causes neurological symptoms that mimic Rett syndrome. *Nat. Genet.* **27**, 322–326 (2001).
7. Garg, S. K. *et al.* Systemic Delivery of MeCP2 Rescues Behavioral and Cellular Deficits in Female Mouse Models of Rett Syndrome. *Journal of Neuroscience* **33**, 13612–13620 (2013).
8. McGraw, C. M., Samaco, R. C. & Zoghbi, H. Y. Adult neural function requires MeCP2. *Science*. **333**, 186–186 (2011).
9. Trevarthen, C. & Daniel, S. Disorganized rhythm and synchrony: early signs of autism and Rett syndrome. *Brain Dev.* **27**(Suppl 1), S25–S34 (2005).
10. Marschik, P. B. *et al.* Changing the perspective on early development of Rett syndrome. *Research in Developmental Disabilities* **34**, 1236–1239 (2013).
11. Neul, J. L. *et al.* Developmental delay in Rett syndrome: data from the natural history study. 1–9, <https://doi.org/10.1186/1866-1955-6-20> (2014).
12. Leonard, H. & Bower, C. Is the girl with Rett syndrome normal at birth? *Dev. Med. Child Neurol.* **40**, 115–121 (1998).
13. Einspieler, C., Kerr, A. M. & Prechtel, H. F. R. Is the Early Development of Girls with Rett Disorder Really Normal? *Pediatr. Res.* **57**, 696–700 (2005).
14. Einspieler, C., Freilinger, M. & Marschik, P. B. Behavioural biomarkers of typical Rett syndrome: moving towards early identification. *Wien Med Wochenschr* **166**, 333–337 (2016).
15. De Filippis, B., Ricceri, L. & Laviola, G. Early postnatal behavioral changes in the *Mecp2*-308 truncation mouse model of Rett syndrome. *Genes, Brain and Behavior* **9**, 213–223 (2010).
16. Lagercrantz, H. & Slotkin, T. A. The ‘Stress’ of Being Born. *Scientific American* **254**, 100–107 (1986).
17. Hillman, N. H., Kallapur, S. G. & Jobe, A. H. Physiology of Transition from Intrauterine to Extrauterine Life. *Clinics in Perinatology* **39**, 769–783 (2012).
18. Hillman, N. H. *et al.* Antenatal and postnatal corticosteroid and resuscitation induced lung injury in preterm sheep. *Respir. Res.* **10**, 124 (2009).
19. Hooper, S. B. *et al.* Cardiovascular transition at birth: a physiological sequence. *Pediatr. Res.* **77**, 608–614 (2015).
20. Olin, A. *et al.* Stereotypic Immune System Development in Newborn Children. *Cell* **174**, 1277–1292.e14 (2018).
21. Schaffert, S. & Khatri, P. Early life immunity in the era of systems biology: understanding development and disease. *Genome Med* **10**, 88 (2018).
22. Tanaka, M. & Nakayama, J. Development of the gut microbiota in infancy and its impact on health in later life. *Allergol Int* **66**, 515–522 (2017).
23. Ben-Ari, Y. Is birth a critical period in the pathogenesis of autism spectrum disorders? *Nat. Rev. Neurosci.* **16**, 498–505 (2015).
24. Curran, E. A. *et al.* Association Between Obstetric Mode of Delivery and Autism Spectrum Disorder: A Population-Based Sibling Design Study. *JAMA Psychiatry* (2015).
25. D’Onofrio, B. M. *et al.* Preterm birth and mortality and morbidity: a population-based quasi-experimental study. *JAMA Psychiatry* **70**, 1231–1240 (2013).
26. Glasson, E. J. *et al.* Perinatal factors and the development of autism: a population study. *Arch Gen Psychiatry* **61**, 618–627 (2004).
27. Mann, J. R., McDermott, S., Bao, H., Hardin, J. & Gregg, A. Pre-Eclampsia, Birth Weight, and Autism Spectrum Disorders. *J Autism Dev Disord* **40**, 548–554 (2009).
28. Lyall, K., Pauls, D. L., Spiegelman, D., Ascherio, A. & Santangelo, S. L. Pregnancy complications and obstetric suboptimality in association with autism spectrum disorders in children of the nurses’ health study II. *Autism Res* **5**, 21–30 (2011).
29. Brimacombe, M., Ming, X. & Lamendola, M. Prenatal and Birth Complications in Autism. *Matern Child Health J* **11**, 73–79 (2006).
30. Tyzio, R. *et al.* Maternal oxytocin triggers a transient inhibitory switch in GABA signaling in the fetal brain during delivery. *Science*. **314**, 1788–1792 (2006).
31. Tyzio, R. *et al.* Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. *Science*. **343**, 675–679 (2014).
32. Eftekhari, S. *et al.* Response to Comment on ‘Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring’. *Science*. **346**, 176–176 (2014).
33. Holmes, G. L. *et al.* Alterations in sociability and functional brain connectivity caused by early-life seizures are prevented by bumetanide. *Neurobiol. Dis.* **77**, 204–219 (2015).
34. He, Q., Nomura, T., Xu, J. & Contractor, A. The developmental switch in GABA polarity is delayed in fragile X mice. *Journal of Neuroscience* **34**, 446–450 (2014).
35. Banerjee, A. *et al.* Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome. *Proc. Natl. Acad. Sci. USA* (2016).
36. Ben-Ari, Y., Gaiarsa, J.-L., Tyzio, R. & Khazipov, R. GABA: A Pioneer Transmitter That Excites Immature Neurons and Generates Primitive Oscillations. *Physiol. Rev.* **87**, 1215–1284 (2007).
37. Dargaev, Z. *et al.* Restoring GABAergic inhibition rescues memory deficits in a Huntington’s disease mouse model. *Proc. Natl. Acad. Sci. USA* **115**, E1618–E1626 (2018).
38. Kee, S. E., Mou, X., Zoghbi, H. Y. & Ji, D. Impaired spatial memory codes in a mouse model of Rett syndrome. *eLife* **7**, 185 (2018).
39. Lu, H. *et al.* Loss and Gain of MeCP2 Cause Similar Hippocampal Circuit Dysfunction that Is Rescued by Deep Brain Stimulation in a Rett Syndrome Mouse Model. *Neuron* **91**, 739–747 (2016).
40. Asaka, Y., Jugloff, D. G. M., Zhang, L., Eubanks, J. H. & Fitzsimonds, R. M. Hippocampal synaptic plasticity is impaired in the *Mecp2*-null mouse model of Rett syndrome. *Neurobiology of Disease* **21**, 217–227 (2006).
41. Moretti, P. *et al.* Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. *Journal of Neuroscience* **26**, 319–327 (2006).
42. Ghoshal, A. *et al.* mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. *Hum. Mol. Genet.* **25**, 1990–2004 (2016).
43. Katz, D. M., Dutschmann, M., Ramirez, J.-M. & Hilaire, G. Breathing disorders in Rett syndrome: Progressive neurochemical dysfunction in the respiratory network after birth. *Respir Physiol Neurobiol* **168**, 101–108 (2009).
44. Johnson, C. M. *et al.* Defects in brainstem neurons associated with breathing and motor function in the *Mecp2*R168X/Y mouse model of Rett syndrome. *AJP: Cell Physiology* **311**, C895–C909 (2016).
45. Viemari, J.-C. *et al.* *Mecp2* deficiency disrupts norepinephrine and respiratory systems in mice. *Journal of Neuroscience* **25**, 11521–11530 (2005).
46. Lemonnier, E. *et al.* Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders. *Transl Psychiatry* **7**, e1124 (2017).
47. Nomura, Y. Early behavior characteristics and sleep disturbance in Rett syndrome. *Brain Dev.* **27**(Suppl 1), S35–S42 (2005).
48. Schüle, B., Armstrong, D. D., Vogel, H., Oviedo, A. & Francke, U. Severe congenital encephalopathy caused by MECP2 null mutations in males: central hypoxia and reduced neuronal dendritic structure. *Clin. Genet.* **74**, 116–126 (2008).
49. Fu, F. *et al.* Prenatal diagnosis of fetuses with congenital abnormalities and duplication of the MECP2 region. *Gene* **546**, 222–225 (2014).



50. Okabe, Y. *et al.* Neural development of methyl-CpG-binding protein 2 null embryonic stem cells: a system for studying Rett syndrome. *Brain Res.* **1360**, 17–27 (2010).
51. Marchetto, M. C. N. *et al.* A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell* **143**, 527–539 (2010).
52. Kim, K.-Y., Hysolli, E. & Park, I.-H. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. *Proc. Natl. Acad. Sci. USA* **108**, 14169–14174 (2011).
53. Petazzi, P. *et al.* An increase in MECP2 dosage impairs neural tube formation. *Neurobiol. Dis.* **67**, 49–56 (2014).
54. Tsujimura, K., Abematsu, M., Kohyama, J., Namihira, M. & Nakashima, K. Neuronal differentiation of neural precursor cells is promoted by the methyl-CpG-binding protein MeCP2. *Exp. Neurol.* **219**, 104–111 (2009).
55. Bedogni, F. *et al.* Defects During Mecp2 Null Embryonic Cortex Development Precede the Onset of Overt Neurological Symptoms. *Cereb. Cortex*, <https://doi.org/10.1093/cercor/bhv078> (2015).
56. Nozawa, K. *et al.* Zebrafish Mecp2 is required for proper axonal elongation of motor neurons and synapse formation. *Dev Neurobiol* **77**, 1101–1113 (2017).
57. Sampathkumar, C. *et al.* Loss of MeCP2 disrupts cell autonomous and autocrine BDNF signaling in mouse glutamatergic neurons. *eLife* **5**, 214 (2016).
58. Cobolli Gigli, C. *et al.* Lack of Methyl-CpG Binding Protein 2 (MeCP2) Affects Cell Fate Refinement During Embryonic Cortical Development. *Cereb. Cortex* **28**, 1846–1856 (2018).
59. Medrihan, L. *et al.* Early Defects of GABAergic Synapses in the Brain Stem of a MeCP2 Mouse Model of Rett Syndrome. *J. Neurophysiol.* **99**, 112–121 (2007).
60. Zhang, Z. W., Zak, J. D. & Liu, H. MeCP2 Is Required for Normal Development of GABAergic Circuits in the Thalamus. *J. Neurophysiol.* **103**, 2470–2481 (2010).
61. Fernandez, A. *et al.* The GABA Developmental Shift Is Abolished by Maternal Immune Activation Already at Birth. *Cereb. Cortex* **130**, e1447 (2018).
62. Corradini, I. *et al.* Maternal Immune Activation Delays Excitatory-to-Inhibitory Gamma-Aminobutyric Acid Switch in Offspring. *Biol. Psychiatry* **83**, 680–691 (2018).
63. Duarte, S. T. *et al.* Abnormal Expression of Cerebrospinal Fluid Cation Chloride Cotransporters in Patients with Rett Syndrome. *PLoS ONE* **8**, e68851 (2013).
64. Tang, X. *et al.* KCC2 rescues functional deficits in human neurons derived from patients with Rett syndrome. *Proc. Natl. Acad. Sci. USA* (2016).
65. Martinowich, K. *et al.* DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. *Science*. **302**, 890–893 (2003).
66. Xu, X., Miller, E. C. & Pozzo-Miller, L. Dendritic spine dysgenesis in Rett syndrome. *Front. Neuroanat.* **8**, 172 (2014).
67. Chang, Q., Khare, G., Dani, V., Nelson, S. & Jaenisch, R. The Disease Progression of Mecp2 Mutant Mice Is Affected by the Level of BDNF Expression. *Neuron* **49**, 341–348 (2006).
68. Balkowiec, A. & Katz, D. M. Brain-derived neurotrophic factor is required for normal development of the central respiratory rhythm in mice. *J. Physiol. (Lond.)* **510**(Pt 2), 527–533 (1998).
69. Kron, M. *et al.* A BDNF loop-domain mimetic acutely reverses spontaneous apneas and respiratory abnormalities during behavioral arousal in a mouse model of Rett syndrome. *Disease Models & Mechanisms* **7**, 1047–1055 (2014).
70. Kohara, K. *et al.* A local reduction in cortical GABAergic synapses after a loss of endogenous brain-derived neurotrophic factor, as revealed by single-cell gene knock-out method. *Journal of Neuroscience* **27**, 7234–7244 (2007).
71. Vicario-Abejón, C., Owens, D., McKay, R. & Segal, M. Role of neurotrophins in central synapse formation and stabilization. *Nat. Rev. Neurosci.* **3**, 965–974 (2002).
72. Porcher, C., Medina, I. & Gaiarsa, J.-L. Mechanism of BDNF Modulation in GABAergic Synaptic Transmission in Healthy and Disease Brains. *Front Cell Neurosci* **12**, 273 (2018).
73. Zhong, W. *et al.* Methyl CpG Binding Protein 2 Gene Disruption Augments Tonic Currents of  $\gamma$ -Aminobutyric Acid Receptors in Locus Coeruleus Neurons: IMPACT ON NEURONAL EXCITABILITY AND BREATHING. *J. Biol. Chem.* **290**, 18400–18411 (2015).
74. Jin, X., Cui, N., Zhong, W., Jin, X.-T. & Jiang, C. GABAergic synaptic inputs of locus coeruleus neurons in wild-type and Mecp2-null mice. *AJP: Cell Physiology* **304**, C844–57 (2013).
75. Voituron, N. & Hilaire, G. The benzodiazepine Midazolam mitigates the breathing defects of Mecp2-deficient mice. *Respir Physiol Neurobiol* **177**, 56–60 (2011).
76. Ma, D. *et al.* Rescue of Methyl-CpG Binding Protein 2 Dysfunction-induced Defects in Newborn Neurons by Pentobarbital. *Neurotherapeutics* **12**, 477–490 (2015).
77. Zhang, W., Peterson, M., Beyer, B., Frankel, W. N. & Zhang, Z.-W. Loss of MeCP2 from forebrain excitatory neurons leads to cortical hyperexcitation and seizures. *Journal of Neuroscience* **34**, 2754–2763 (2014).
78. Zhang, L., He, J., Jugloff, D. G. M. & Eubanks, J. H. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. *Hippocampus*. **18**, 294–309 (2008).
79. Chao, H. T. *et al.* Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes1. *Nature* **468**, 263–269 (2010).
80. Calfa, G., Li, W., Rutherford, J. M. & Pozzo-Miller, L. Excitation/inhibition imbalance and impaired synaptic inhibition in hippocampal area CA3 of Mecp2 knockout mice. *Hippocampus*. **25**, 159–168 (2015).
81. Li, W., Xu, X. & Pozzo-Miller, L. Excitatory synapses are stronger in the hippocampus of Rett syndrome mice due to altered synaptic trafficking of AMPA-type glutamate receptors. *Proc. Natl. Acad. Sci. USA* **113**, E1575–84 (2016).
82. Banerjee, A. *et al.* Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. *Int. J. Neuropsychopharmacol.* **16**, 1309–1318 (2013).
83. Dani, V. S. *et al.* Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. *Proc. Natl. Acad. Sci. USA* **102**, 12560–12565 (2005).
84. Bodda, C. *et al.* Mild overexpression of Mecp2 in mice causes a higher susceptibility toward seizures. *Am. J. Pathol.* **183**, 195–210 (2013).
85. Nissenkorn, A. *et al.* Epilepsy in Rett syndrome—the experience of a National Rett Center. *Epilepsia* **51**, 1252–1258 (2010).
86. He, L.-J. *et al.* Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity. *Nat Commun* **5**, 5036 (2014).
87. Ito-Ishida, A., Ure, K., Chen, H., Swann, J. W. & Zoghbi, H. Y. Loss of MeCP2 in Parvalbumin- and Somatostatin-Expressing Neurons in Mice Leads to Distinct Rett Syndrome-like Phenotypes. *Neuron* **88**, 651–658 (2015).
88. Otani, S. & Connor, J. A. Requirement of rapid Ca<sup>2+</sup> entry and synaptic activation of metabotropic glutamate receptors for the induction of long-term depression in adult rat hippocampus. *J Physiol (Lond)* **511**(Pt 3), 761–770 (1998).
89. Palmer, M. J., Irving, A. J., Seabrook, G. R., Jane, D. E. & Collingridge, G. L. The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. *Neuropharmacology* **36**, 1517–1532 (1997).
90. Oliet, S. H., Malenka, R. C. & Nicoll, R. A. Two distinct forms of long-term depression coexist in CA1 hippocampal pyramidal cells. *Neuron* **18**, 969–982 (1997).

91. Deidda, G. *et al.* Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. *Nat Med* **21**, 318–326 (2015).
92. Pavlov, I., Riekkki, R. & Taira, T. Synergistic action of GABA-A and NMDA receptors in the induction of long-term depression in glutamatergic synapses in the newborn rat hippocampus. *Eur J Neurosci* **20**, 3019–3026 (2004).
93. Lopez-Samblas, A. M., Adams, J. A., Goldberg, R. N. & Modi, M. W. The pharmacokinetics of bumetanide in the newborn infant. *Biol. Neonate* **72**, 265–272 (1997).
94. Ben-Ari, Y. The Yin and Yen of GABA in Brain Development and Operation in Health and Disease. *Front. Cell Neurosci.* **6**, 45 (2012).
95. Melchior, M. *et al.* Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation. *Pain* **1** (2018).
96. Mazzuca, M. *et al.* Newborn Analgesia Mediated by Oxytocin during Delivery. *Front Cell Neurosci* **5**, 3 (2011).
97. Meziane, H. *et al.* An Early Postnatal Oxytocin Treatment Prevents Social and Learning Deficits in Adult Mice Deficient for Magel2, a Gene Involved in Prader-Willi Syndrome and Autism. *Biol. Psychiatry* (2014).
98. Schaller, F. *et al.* A single postnatal injection of oxytocin rescues the lethal feeding behaviour in mouse newborns deficient for the imprinted Magel2 gene. *Hum. Mol. Genet.* **19**, 4895–4905 (2010).
99. Muscatelli, F., Desarmenien, M. G., Matarazzo, V. & Grinevich, V. Oxytocin Signaling in the Early Life of Mammals: Link to Neurodevelopmental Disorders Associated with ASD. *Curr Top Behav Neurosci* (2017).
100. Tauber, M. *et al.* The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader-Willi Syndrome. *PEDIATRICS* **139**, e20162976 (2017).
101. Toda, T. *et al.* Birth Regulates the Initiation of Sensory Map Formation through Serotonin Signaling. *Dev. Cell* **27**, 32–46 (2013).
102. Toda, T. & Kawasaki, H. The development of suckling behavior of neonatal mice is regulated by birth. *Molecular Brain* **7**, 8 (2014).
103. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).
104. Bulletin, N. C. P. Dominance statistics: Ordinal analyses to answer ordinal questions. *psycnet.apa.org* (1993).

## Acknowledgements

We are grateful to C Dumon, R Cloarec, B Riffault, A Dufour, L-A Gouty-Colomer, V Matarazzo, F Michel, D Diabira, and A Fernandez for their contributions to some of the experiments, and N Burnashev for criticism. Financial support was provided by Neurochlore; Fondation Bettencourt Schueller; France's Agence Nationale de la Recherche (ANR-14-CE13-0021-01); and Fondation de France (no 2014-00052268).

## Author Contributions

Y.B.-A. project leader. Y.B.-A., N.L., D.C.F. and J.-L.G. design of experiments. Y.B.-A., N.L. and D.C.F. writing paper. N.L., R.N., R.T., M.C., A.P.-B., D.G. and J.-L.G. electrophysiological experiments. S.E.: immunohistochemistry experiments. T.-T.B.: respiration studies. M.B.-G. genotyping and bumetanide pretreatment. M.C., T.-T.B. and M.B.-G. evaluation of weight gain and onset of mortality. N.L., R.N., R.T., M.C., S.E., J.R., P.B., D.G. and J.-L.G. analysis and statistics. All authors discussed the results and commented on the manuscript. R.N. current address: The Solomon H. Snyder Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, Maryland. A.P.-B. current address: Neurochlore.

## Additional Information

**Supplementary information** accompanies this paper at <https://doi.org/10.1038/s41598-019-45635-9>.

**Competing Interests:** N.L., R.N., R.T., M.C., S.E., T.-T.B., D.G., D.C.F. and Y.B.-A. are or were paid by Neurochlore, a biotech company dedicated to the development of treatments for children with autism. N.L., R.N., R.T., D.C.F. and Y.B.-A. are shareholders of Neurochlore. Y.B.-A. is CEO of Neurochlore.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019